sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective

Table 1

Treatment scenario and services provided for the outpatient setting (low and intermediate follow-up).

Service	Initial consultation (all patients)	Outpatient management
		Low follow-up	Intermediate follow-up
Duration	—	8 weeks	8 weeks
Consultation	1x	Every 7-10 days (6x)	Weekly (8x)
Blood pressure measurement	1x	Every 7-10 days (6x)	Weekly (8x)
Blood analyses (ALAT/GPT, ASAT/GOT, LDH, haptoglobin, creatinine)	1x	—	Weekly (8x)
Fetal ultrasound with Doppler/CTG	1x	Every 7-10 days (6x)	Weekly (8x)
Proteinuria (quantitative)	1x	—	—
Proteinuria (fast strip)	—	Every 7-10 days (6x)	Weekly (8x)
sFlt-1/PlGF ratio	1x	—	—
Costs per week (€)	531	200	547

Based on the assumption that a proportion of women would be hospitalized after 4 weeks. ALAT/GPT: alanine aminotransferase; ASAT/GOT: aspartate aminotransferase; CTG: cardiotocography; LDH: lactate dehydrogenase; PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.